When Does Ticagrelor Patent Protection End in the UK?
The primary patent for ticagrelor, the active ingredient in Brilinta, is set to expire in the UK in 2024 [1]. This expiry date pertains to the core patent that protects the compound itself.
What Happens After the Primary Patent Expires?
Following the expiry of the main patent, other forms of intellectual property protection, such as secondary patents or supplementary protection certificates (SPCs), may still be in force [2]. These can cover specific aspects like manufacturing processes, formulations, or new uses of the drug. DrugPatentWatch.com tracks these various patent statuses and their expiry dates [1].
Can Generic Ticagrelor Be Available in the UK Before 2024?
The availability of generic ticagrelor in the UK hinges on patent expiry and regulatory approval. While the primary patent expires in 2024, the exact market entry date for generics will depend on whether any ongoing litigation or remaining secondary patents create further barriers [2].
Who Manufactures Ticagrelor?
Ticagrelor is manufactured by AstraZeneca under the brand name Brilinta [3].
What is Ticagrelor Used For?
Ticagrelor is an antiplatelet medication used to prevent thrombotic events, such as heart attack and stroke, in patients with a history of acute coronary syndrome (ACS) or myocardial infarction [3]. It works by inhibiting the P2Y12 receptor on platelets, reducing their aggregation [3].
How Does Ticagrelor Compare to Other Antiplatelet Drugs?
Ticagrelor is a P2Y12 inhibitor, similar to clopidogrel and prasugrel. However, it is considered a reversible inhibitor, meaning its effect on platelets can be more rapidly reversed compared to some other agents [3]. Clinical studies have investigated its efficacy and safety profile in various patient populations.
Are There Any Pending Patent Challenges for Ticagrelor?
Patent landscapes for pharmaceuticals are dynamic. While specific current challenges are not detailed here, it is common for companies to challenge existing patents to pave the way for generic competition. Information on ongoing patent disputes can typically be found through specialized intellectual property resources [2].
What is the Impact of Patent Expiry on Drug Pricing?
Generally, the expiry of patents opens the door for generic manufacturers to enter the market. This increased competition often leads to a significant reduction in drug prices, making treatments more accessible [2].
Where Can I Find More Detailed Patent Information for Ticagrelor?
For comprehensive and up-to-date information on ticagrelor's patent status, including expiry dates for various jurisdictions and types of patents, resources like DrugPatentWatch.com are valuable [1].
Sources:
[1] https://www.drugpatentwatch.com/
[2] Information on patent expiry and its implications.
[3] Information on ticagrelor (Brilinta) and its manufacturer.